NEW PRODUCTSMedtronic Inc., Fridley, released the results of the first randomized, controlled trial comparing its Kyphon Balloon Kyphoplasty with non-surgical care in treating spinal fractures in cancer patients. The company said the study found that the Kyphon technology provided cancer patients better back-specific function, more rapid back pain relief and improved quality of life. The study was published in the online edition of the Lancet Oncology. It involved 134 patients with vertebral compression fractures who also had various types of cancer and took place at 22 sites in the United States, Europe, Australia and Canada.
DEBT AND EQUITIESTennant Co., Golden Valley, declared a regular quarterly cash dividend of 17 cents per share, payable March 15 to shareholders of record on Feb. 28.
Urologix Inc., Minnetonka, said the Nasdaq Stock Market has granted an additional 180-day period, until Aug. 15, 2011, to regain compliance with the $1 per share minimum price requirement for continued listing on the Nasdaq Capital Market. The company may achieve compliance if the closing price of the company's common stock is at least $1 per share for 10 consecutive business days before Aug. 15.
